Kala's lead product shows promise in two eye indications
This article was originally published in Scrip
Executive Summary
The Massachusetts-based ophthalmic company Kala Pharmaceuticals has reported positive data for its formulation of the steroid loteprednol etabonate KPI-121 in two indications, pain in cataract surgery and dry eye disease.